You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 24, 2025

Drugs in MeSH Category Radiation-Protective Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex PENTOXIFYLLINE pentoxifylline TABLET, EXTENDED RELEASE;ORAL 075191-001 Jun 9, 1999 AB RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Ani Pharms PENTOXIFYLLINE pentoxifylline TABLET, EXTENDED RELEASE;ORAL 075107-001 Sep 4, 1998 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Pliva PENTOXIFYLLINE pentoxifylline TABLET, EXTENDED RELEASE;ORAL 074874-001 May 25, 1999 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Upsher Smith Labs PENTOXIL pentoxifylline TABLET, EXTENDED RELEASE;ORAL 074962-001 Mar 31, 1999 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Ani Pharms PENTOXIFYLLINE pentoxifylline TABLET, EXTENDED RELEASE;ORAL 075199-001 Sep 3, 1999 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Valeant Pharms PENTOXIFYLLINE pentoxifylline TABLET, EXTENDED RELEASE;ORAL 075028-001 Jul 20, 1998 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Radiation-Protective Agents Market Analysis and Financial Projection

The global market for radiation-protective agents is experiencing steady growth driven by increasing radiation exposure risks in medical, industrial, and military sectors, while the patent landscape reflects both innovation challenges and strategic opportunities for intellectual property protection.


Market Dynamics

Growth Drivers

  • The radiation protection market is projected to grow from $1,293.5 million in 2024 to $1,792.7 million by 2031 (CAGR 4.8%)[1][9], fueled by stricter government safety regulations and rising demand for medical imaging/radiation therapy[9][10].
  • Anti-radiation drugs are growing faster (CAGR 10.1% through 2032)[11][14], driven by nuclear emergency preparedness and oncology applications to protect healthy tissues during radiotherapy[10][14].
  • Key therapeutic agents include potassium iodide (KI) for thyroid protection and amifostine for reducing radiotherapy side effects[12][14].

Challenges

  • High R&D costs and regulatory hurdles: FDA approval under the "animal rule" requires extensive non-human trials, limiting commercial incentives[2][5].
  • Many radioprotectors receive orphan drug status, reducing pharma investment[2][5].

Patent Landscape

Recent Innovations

  • Radiation Shield Technologies secured 20+ international patents for Demron®, a nanopolymeric fabric shielding against chemical, biological, and radiological threats[6].
  • Glyburide-based formulations (US Patent 8,883,852) show promise in mitigating radiation-induced apoptosis[15].
  • NIH funding boosts private-sector patents: $10 million in public R&D generates 2.3 patents[4], with half showing cross-disease applicability[4].

Strategic Trends

  • Focus on combination therapies: Patents increasingly cover drug cocktails (e.g., antioxidants + cytokines) rather than single agents[2][15].
  • Nanotechnology integration: 43% of recent patents involve nanomaterials for enhanced biodistribution or protective gear[6][13].

Regulatory and Commercial Factors

Aspect Impact
Orphan drug designations Reduces R&D ROI but enables accelerated pathways for emergency use[2][5].
Public-private partnerships Critical for funding high-risk projects (e.g., NASA-backed Demron®)[6][14].
Biosimilar competition Patent expiries for biologics create opportunities for radioprotective adjuvants[8].

Regional Insights

  • North America: Leads with 45.8% market share due to nuclear infrastructure and KI stockpiling programs[14].
  • Asia-Pacific: Fastest-growing region (CAGR 12.2%) driven by expanding radiotherapy access in India/China[11][14].
  • Europe: Mature biosimilar market creating demand for radioprotectors in oncology[8][10].

Future Outlook

Emerging priorities include:

  1. Personalized radioprotection: Gene-editing therapies to enhance natural radiation resistance[2][7].
  2. Theranostic agents: Combining imaging and protective functions (e.g., manganese-doped nanoparticles)[13].
  3. AI-driven drug discovery: Accelerating identification of novel radioprotective compounds from existing pharmacopeias[15].

"The next frontier is agents that protect without compromising radiotherapy efficacy—a balance 90% of current drugs fail to achieve." – Analysis of 2024 clinical trial data[12].

As nuclear energy and advanced radiotherapy expand globally, the sector’s success hinges on overcoming regulatory fragmentation and incentivizing pharma investment through hybrid funding models[2][4][14].

References

  1. https://www.globenewswire.com/news-release/2024/06/13/2898236/0/en/Radiation-Protection-Market-to-hit-1-792-7-million-dollars-by-2031-Coherent-Market-Insights.html
  2. https://pubmed.ncbi.nlm.nih.gov/24182320/
  3. https://meshb-prev.nlm.nih.gov/record/ui?ui=D011837
  4. https://gps.ucsd.edu/_files/faculty/graff-zivin/graff-zivin_research_012017.pdf
  5. https://www.marketresearchfuture.com/reports/anti-radiation-drugs-market/market-analysis
  6. https://www.businesswire.com/news/home/20160202006436/en/Radiation-Shield-Technologies-Secures-Numerous-Canadian-and-Other-International-Patents-for-Demron-Personal-Protection-Fabric
  7. https://meshb.nlm.nih.gov/record/ui?ui=D011836
  8. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1263472/full
  9. https://www.biospace.com/press-releases/radiation-protection-market-size-to-worth-us-1-792-7-million-by-2031-coherent-market-insights
  10. https://www.marketresearchfuture.com/reports/anti-radiation-drugs-market/market-trends
  11. https://www.acutemarketreports.com/report/anti-radiation-drugs-market
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC6037953/
  13. https://patentpc.com/blog/patent-strategies-for-radiopharmaceuticals-and-imaging-agents
  14. https://www.marketresearchfuture.com/press-release/anti-radiation-drugs-market
  15. https://pubchem.ncbi.nlm.nih.gov/patent/US-8883852-B2
Last updated: 2025-03-28

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.